Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer

Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer

The study objective is to evaluate the added value of MIRA technology as an adjunct to mammography in the detection of malignant breast lesions in women with dense breast and/or at elevated risk of breast cancer.

Study Overview

• Status: Unknown
• Conditions: Breast Cancer
• Intervention / Treatment: Device: MIRA device imaging

• Study Type: Interventional
• Enrollment (Anticipated): 1200
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Italy
  • San Donato Milanese, Italy
    • Recruiting
    • Policlinico San Donato
    • Contact: Francesco Sardanelli, M.D.; Phone Number: 39-02-52774468; Email: f.sardanelli@grupposandonato.it

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 24 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

**Calibration Phase:

A.Subjects who are asymptomatic and scheduled to undergo routine screening mammography.

OR

B.Subjects scheduled for image guided needle biopsy as a result of findings obtained during standard of care (mammography, ultrasound and/or MRI)

**Testing Phase:

A. Subjects scheduled to undergo routine screening mammography and at least one of the following :

• Subjects whose most recent (within 3 years) prior mammogram was interpreted as heterogeneously dense (ACR BI-RADS Breast Density 3) or extremely dense (ACR BI-RADS Breast Density 4).
• Subjects whose current 10-year IBIS breast cancer risk is 5% or higher.

EXCLUSION CRITERIA, valid for both calibration and testing phases:

1. Male by birth.
2. Individual is less than 24 years old.
3. Contraindication to bilateral mammography or MRI.
4. Subjects who are unable to read, understand and execute the informed consent procedure.
5. Subjects who have had mammography, ultrasound or MRI examination performed on the day of the study prior to MIRA scan.
6. Subjects who have significant existing breast trauma.
7. Subjects who have undergone lumpectomy/mastectomy.
8. Subjects who have undergone breast reduction or breast augmentation.
9. Subjects who have undergone any other type of breast surgery.
10. Subjects who have large breast scar / Breast deformation.
11. Subjects who have undergone a breast needle biopsy within the 6 month period prior to their intended enrollment into the study.
12. Subjects who have a temperature > 100° F (37.8C) degrees on the day of the MIRA imaging.
13. Subjects who are pregnant or lactating.
14. Subjects who have had placement of an internal breast marker.
15. Subjects with known Raynaud's Disease.
16. Subjects that are claustrophobic or have physical limitations that do allow them to sit in the system chair for the required imaging session.
17. Subjects with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices.
18. Subjects with a BI-RADS category 6 (e.g. for which mammogram was performed for the purpose of planning cancer therapy).
19. Subjects affected with epilepsy.
20. Subjects who participated in the Calibration Phase will not be able to participate in the Testing Phase.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MIRA device imaging; MIRA Device imaging for adjunctive detection of breast cancer	Device: MIRA device imaging; MIRA Device imaging for adjunctive detection of breast cancer; Other Names: Real Imager 8

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Increase in incremental cancer detection rate	Statistically significant increase of 30% or more in incremental cancer detection rate	24 months

Collaborators and Investigators

• Sponsor: Real Imaging Ltd.
• Investigators: Principal Investigator: Francesco Sardanelli, M.D, Policlinico San Donato

Study record dates

Study Major Dates

• Study Start (Actual): May 23, 2017
• Primary Completion (Anticipated): September 1, 2019
• Study Completion (Anticipated): September 1, 2021

Study Registration Dates

• First Submitted: September 18, 2017
• First Submitted That Met QC Criteria: September 25, 2017
• First Posted (Actual): September 28, 2017

Study Record Updates

• Last Update Posted (Actual): June 19, 2018
• Last Update Submitted That Met QC Criteria: June 17, 2018
• Last Verified: June 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: 960-CLP-ITL_RI8 _ITS1

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No